This phase I trial compares the effect of quercetin and dasatinib to observation alone to decrease premature aging in patients who have undergone a stem cell transplant. Quercetin and dasatinib are drugs that remove specific cells, called “senescent cells.” These senescent cells may contribute to the weakening of bodily function. Giving quercetin and dasatinib may help to prevent certain age-related diseases in patients who have undergone a stem cell transplant.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02652052.
PRIMARY OBJECTIVES:
I. To evaluate the association of frailty with measures of premature aging in hematopoietic stem cell transplantation (HSCT) survivors.
II. To evaluate senescence related parameters in HSCT survivors as a proof of concept study.
III. To evaluate the effect and safety of senolytic drugs in HSCT survivors.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo observation over 180 days. Patients also undergo blood sample collections, skin biopsies, transthoracic echocardiography (TTE) and high resolution periheral quantitative computed tomography (HR-pQCT) scans throughout study.
ARM II: Patients receive quercetin and dasatinib orally (PO) once daily (QD) for 3 consecutive days. Patients also undergo blood sample collections, skin biopsies, TTE and HR-pQCT scans throughout study.
After completion of study treatment, patients in Arm II are followed up for 180 days. Patients also undergo blood sample collection and skin biopsies throughout study.
Trial PhasePhase I
Trial Typesupportive care
Lead OrganizationMayo Clinic in Rochester
Principal InvestigatorSuzanne R. Hayman
